Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 4/20 | 0.40 |
| ▸ | CES1 | P23141 | 4/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | PAK4 | O96013 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | LYN | P07948 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16122077 | 0.83 | ALDH1A1 (0.41) | ALDH1A1ALOX15CES2CES1DGAT1 | |
| SCHEMBL27346257 | 0.82 | ALDH1A1 (0.39) | ALDH1A1ALOX15CES2CES1KDM1A | |
| SCHEMBL147599 | 0.81 | ALDH1A1 (0.52) | ALDH1A1ALOX15CES2CES1HPGD | |
| SCHEMBL31184721 | 0.81 | ALDH1A1 (0.52) | ALDH1A1ALOX15CES2CES1HPGD | |
| SCHEMBL3540940 | 0.80 | CYP1A2 (0.44) | ALDH1A1ALOX15CES2CES1DGAT1 | |
| SCHEMBL28221345 | 0.78 | DGAT1 (0.52) | ALDH1A1CES2CES1KDM1AKCNH2 | |
| SCHEMBL525011 | 0.77 | CES2 (0.67) | ALDH1A1ALOX15CES2CES1HPGD | |
| SCHEMBL28221635 | 0.77 | ALDH1A1 (0.47) | ALDH1A1ALOX15CES2CES1DGAT1 | |
| SCHEMBL9860903 | 0.76 | HPGD (0.55) | ALDH1A1ALOX15CES2CES1HPGD | |
| SCHEMBL29544731 | 0.76 | HPGD (0.55) | ALDH1A1ALOX15CES2CES1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105859543-A | Method for preparing 2, 6-difluoro-4-bromo-benzoyl chloride | 蚌埠中实化学技术有限公司 | 2016-08-17 | — | — | CN | claimed |
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-08-12 | — | — | US | disclosed |
| CN-115667253-B | Compounds useful for inhibiting RET kinase | 伊莱利利公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-4240738-B1 | PYRAZOLE DERIVATIVES AS RET KINASE INHIBITORS | LILLY CO ELI (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4143184-B1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | LILLY CO ELI (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4359402-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | Theravance Biopharma R&D IP, LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11970485-B2 | RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| US-11964968-B2 | Compounds useful for inhibiting RET kinase | ELI LILLY AND COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| CN-117813298-A | Imidazole indazole compounds as JAK inhibitors | 施万生物制药研发IP有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2022272020-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022272020-A1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022192162-A1 | NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| WO-2022098970-A1 | PYRAZOLE DERIVATIVES ASR ET KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220144816-A1 | RET KINASE INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20210363140-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | LOXO ONCOLOGY, INC. | 2021-11-25 | — | — | US | disclosed |
| WO-2021222017-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | ELI LILLY AND COMPANY (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2017046605-A1 | ANTIBACTERIAL COMPOUNDS | REDX PHARMA PLC (GB) | 2017-03-23 | — | — | WO | disclosed |
| CN-105859543-A | Method for preparing 2, 6-difluoro-4-bromo-benzoyl chloride | 蚌埠中实化学技术有限公司 | 2016-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363140-A1 | COMPOUNDS USEFUL FOR INHIBITING RET KINASE | RET, GFRA3, GFRA1 | ALDH1A1 2702/4885ALOX15 4694/4885CES2 4049/4885 |
| US-11970485-B2 | RET kinase inhibitors | RET, BRAF, GFRA1 | ALDH1A1 1205/4885ALOX15 4350/4885CES2 4120/4885 |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | JAK1, JAK3, JAK2 | ALDH1A1 2112/4885ALOX15 939/4885CES2 4746/4885 |
| US-11964968-B2 | Compounds useful for inhibiting RET kinase | RET, GFRA3, GFRA1 | ALDH1A1 2702/4885ALOX15 4694/4885CES2 4049/4885 |
| US-20220144816-A1 | RET KINASE INHIBITORS | RET, BRAF, GFRA1 | ALDH1A1 1205/4885ALOX15 4350/4885CES2 4120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.